Research

*February 2025* In this video, Stephen Liu, MD, of the Georgetown University School of Medicine and Georgetown's Lombardi Comprehensive Cancer Center in Washington, DC, joined Lung Cancers Today to discuss the recent announcement that the phase 3 MARIPOSA trial met its final pre-specified secondary endpoint of overall survival (OS). The…

*November 2024* In this video, Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, discuss the next steps for biomarker testing in NSCLC. Watch here.  

*November 2024* Nicolas Girard, MD, professor, respiratory medicine, Versailles Saint Quentin University; head, Curie-Montsouris Thorax Institute, chair, Medical Oncology Department, Institut Curie, discusses de novo vs acquired resistance alterations in HER2-positive non–small cell lung cancer (NSCLC). In HER2-positive NSCLC, alterations can be broadly categorized as either de novo mutations or acquired resistance mutations, Girard begins. De novo mutations…

*November 2024* Key Takeaways Datopotamab deruxtecan targets EGFR-mutated advanced NSCLC, showing promising response and disease control rates in the TROPION-Lung05 trial. The TROPION-Lung01 trial showed non-significant overall survival improvement, leading to the withdrawal of the BLA for nonsquamous NSCLC. Safety data indicated that all patients experienced treatment-emergent adverse effects, with…

*October 2024* Abstract Purpose This multicenter, randomized, phase III clinical trial (Northern Radiation Oncology Group of China-002) focused on patients with oligo-organ metastatic non–small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) mutations. We aimed to investigate whether first-line concurrent thoracic radiotherapy (TRT) and EGFR-tyrosine kinase inhibitors…

*November 2024* LCRF’s 2024 Scientific Symposium was held November 4 as part of their Lung Cancer Awareness Month activities. Joining the record-breaking group online were event lead and moderator, Kathryn O’Donnell, PhD; chat moderator, Isabel Preeshagul, DO, MBS; and speakers Brendon M. Stiles, MD; Colleen Conner Ziegler; Mark Awad, MD,…

*October 2024* Abstract Purpose This multicenter, randomized, phase III clinical trial (Northern Radiation Oncology Group of China-002) focused on patients with oligo-organ metastatic non–small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) mutations. We aimed to investigate whether first-line concurrent thoracic radiotherapy (TRT) and EGFR-tyrosine kinase inhibitors…